Biohaven Ltd.
biohaven.comBiohaven Ltd (NYSE: BHVN) is a clinical-stage biopharmaceutical company developing drug candidates across neuroscience, immunology, and oncology. The company generates no product revenue as of FY2025, operating entirely on capital raises and debt financing while advancing its pipeline toward regulatory approval. Biohaven was separated from its former parent and began operating as an independent public company in 2022, listing under File No. 001-41477. CEO Vlad Coric, M.D. previously led the former parent through the FDA approval and commercial launch of Nurtec ODT (rimegepant) for migraine and zavegepant (Zavzpret). Biohaven's lead pipeline candidate, troriluzole, is being developed for spinocerebellar ataxia (SCA) in adults, with a planned neurological specialty sales force for U.S. commercialization if approved. The company entered a Note Purchase Agreement with Beetlejuice SA LLC, an affiliate of Oberland Capital Management, in April 2025, recording notes payable at fair value of $238.9 million as of December 31, 2025.
Products & Services
Lead pipeline candidate: troriluzole, in development for spinocerebellar ataxia (SCA) in adults. The company also references prior involvement in the development of rimegepant (Nurtec ODT) and zavegepant (Zavzpret) through its former parent. Pipeline spans neuroscience, immunology, and oncology therapeutic areas, per the FY2025 10-K.
Revenue Model
Biohaven has no approved products and generates no product revenue as of FY2025. The company is funded through equity issuances and debt, including a Note Purchase Agreement with an affiliate of Oberland Capital Management initially measured at $255.8 million in April 2025. Future revenue, if any, would come from product sales, licensing arrangements, or distribution partnerships upon regulatory approval of pipeline candidates.
Customers & Markets
No commercial customers as of FY2025. Target end markets, upon approval, are neurological specialty prescribers and patients with spinocerebellar ataxia in the United States, with potential global expansion via licensing or distribution arrangements.
Geographic Exposure
Primary commercial focus is the United States, per the FY2025 10-K. Global expansion for troriluzole and other candidates is described as contingent on approval and potential partnerships.
Financial Snapshot
Loading...
